ONE-DAY VIRTUAL CONFERENCE - April 17, 2021




CANM VIRTUAL CONFERENCE- APRIL 17, 9 AM- 4 PM ET



NEUROENDOCRINE TUMORS:

THERANOSTICS AND PATIENT MANAGEMENT, A CANADIAN PERSPECTIVE


Register Here



Program

Overall objectives of the one-day virtual conference:


1.   Review the current management of Neuroendocrine Tumors and how Nuclear Medicine Theranostics apply.

2.   Analyze the current status of Nuclear Theranostics practice as it relates to the Canadian Healthcare System.

3.   Update on future prospective for Neuroendocrine Tumors management. 

4.   Create an opportunity for interaction between physicians to discuss the expansion of Neuroendocrine Theranostics.


25% of allowed time to each speaker will be reserved for questions from participants.


 TIME  TITLE  SPEAKER  CHAIR / MODERATOR
 0900-0905  Welcome & instructions    Shereen Ezzat & Andrew Ross
0905-0925

 Introduction to the Expanding World of Nuclear Theranositics - Clinical 

Steve Burrell Andrew Ross
0925-0950

 Introduction to the Expanding World of Nuclear Theranostics-Radiopharmaceutical Science

Alan Packard  Jean-Luc Urbain
0950-1000  Q & A

1000-1030

 Clinical Overview of NET 

Shereen Ezzat

 Andrew Ross
1030-1045  BREAK    
1045-1115  Pathology of NET

Sylvia Asa

 Jean-Luc Urbain
1115-1145

 Surgery of NET

Calvin Law 

 Shereen Ezzat
1145-1215

 Radiation Therapy of NET 

Rebecca Wong Andrew Ross
1215-1245

 Panel Discussion and Q & A  

  Salem Yuoness
1245-1330  LUNCHEON    
1330-1430

 Nuclear Medicine Imaging of NETs:

 Past, Present & Future

 177 Lutetium Dotatate Therapy of NET's: The Nuts & Bolts

Éric Turcotte

David Laidley
 François Lamoureux
1430-1530  Case Discussion

Daniel Rayson, David Laidley, Janice Pasieka & Shereen Ezzat

 Shereen Ezzat
1515-1600  NET Forum - Q & A  ALL  Andrew Ross
Faculty List


Asa, Sylvia 

Sylvia L. Asa, MD, PhD, Endocrine Pathologist, University Hospitals Cleveland and University Health Network, Toronto, and Professor of Pathology, Case Western Reserve University, has published over 500 scientific articles and 100 book chapters, written seven books, co-edited seven books and given over 250 invited lectures. She serves on numerous editorial boards of scientific journals. Dr. Asa was President of the Endocrine Pathology Society (1997–1998) and the US-Canadian Academy of Pathology (2005-6) and has received awards from national and international scientific organizations.

As head of the largest pathology department in Canada for 15 years, Dr. Asa made innovative changes to the practice of the discipline, implementing subspecialization, molecular diagnostics, biobanking, automation, pathology informatics and digital pathology.  She emphasized the importance of education and research. To ensure public knowledge of the role of Pathology and maintain a direct connection with patients, Dr. Asa is a consultant to several patient groups.


 

Burrell, Steven

Dr. Burrell is head of Nuclear Medicine at the QEII Health Sciences Centre and a Professor of Radiology at Dalhousie University. He has been research director for Dalhousie/QEII Radiology and residency program director for Dalhousie Nuclear Medicine. His clinical and research interests include imaging of cancer, cardiac disease, and osteoporosis.



 


Ezzat, Shereen

Shereen Ezzat, M.D., FRCP(C), FACP, Professor of Medicine & Oncology, Endocrine Oncology Site Group, Princess Margaret Cancer Centre, University Health Network.  Dr. Ezzat obtained his medical degree from the University of Manitoba, completed his residency training at the University of British Columbia, and his post-doctoral research training in molecular oncology at Cedars-Sinai-UCLA School of Medicine in Los Angeles.

Dr. Ezzat has authored or co-authored more than 250 original research articles and 40 invited review articles, and he has delivered more than 150 invited lectures. He supervises undergraduate and graduate students, as well as postdoctoral fellows. He teaches a number of courses, including physiology, biochemistry, and developmental biology.

Dr. Ezzat served as an Editorial Board member for a number of journals including Endocrinology, Journal of Clinical Endocrinology & Metabolism, American Journal of Physiology, Journal of Endocrinology, Endocrine Practice, and BMJ-Endocrine. He is a regular reviewer for the New England Journal of Medicine and the Annals of Internal Medicine.

Dr. Ezzat belongs to a number of professional societies, including the Endocrine Society, Federation of American Societies for Experimental Biology (FASEB), the Pituitary Society, the American College of Physicians, and the Royal College of Physicians & Surgeons of Canada.   He is equally committed to patient advocacy and serves as an advisor to a number of organizations including the Canadian Neuroendocrine Tumor Society (CNETS), Thyroid Cancer Canada, and the Pituitary Network Association.


 

Law, Calvin

Dr. Calvin Law is the Chief, Edmond Odette Cancer Centre, Sunnybrook Health Sciences Centre and Regional Vice President, Cancer Care Ontario. He is also a cancer surgeon specializing in hepatobiliary, pancreatic and gastrointestinal surgical oncology and holds the rank of Full Professor in the Department of Surgery and the Department of Health Policy, Management and Evaluation at the University of Toronto. He is an Affiliate Scientist at the Sunnybrook Research Institute. Dr. Law completed his MD at the University of Toronto, trained in General Surgery at McMaster University, completed a fellowship in Surgical Oncology at the University of Toronto and received his Master of Public Health from Harvard University. He has authored 180 peer reviewed publications, won numerous teaching awards at the undergraduate, postgraduate and fellowship levels, and is completing his twentieth year on faculty at the University of Toronto.

 

Packard, Alan

Dr. Packard received his Bachelor’s Degree in chemistry from the University of New Hampshire, where he did undergraduate research in chemical oceanography, and his PhD in inorganic chemistry from Colorado State University, where he studied Jahn-Teller distortions in copper complexes. His first exposure to nuclear medicine was as a postdoctoral fellow at the University of Cincinnati where he synthesized 99Tc complexes of aminopolycarboxylate ligands (e.g., EDTA). This was followed by two years as an Assistant Scientist at Brookhaven National Laboratory where he continued his investigations into technetium chemistry. In 1982 he moved to Boston Children’s Hospital where he is now a Sr. Research Associate in Nuclear Medicine and Director of Radiopharmaceutical Research and an Associate Professor Radiology at Harvard Medical School. His research interests still include radiometals, but have shifted from 99mTc to 64/67Cu- and 89Zr-labeled proteins and now also include 18F chemistry where his research is primarily focused on the development of an18F-labeled myocardial perfusion agent.



 

Pasieka, Janice 

Dr. Janice L Pasieka graduated from the University of Western Medical School and did her General Surgery Training at the University of Calgary. She then did two and a half years of Endocrine Surgical Training. The first year was spent in Dr David Hanley’s lab at the University of Calgary, then a year at the University of Michigan, under the mentorship of Dr. Norman Thompson followed by time at the Karolinska Institute in Stockholm, Sweden with Professor Bertil Hamberger. She then returned to Calgary and has devoted her clinical practice solely to endocrine surgical diseases. At the Tom Baker Clinic Center, Dr Pasieka was the driving force behind the development of a multidisciplinary clinic for Neuroendocrine Tumors as well as the Multidisciplinary Hereditary Endocrine Clinic. She is responsible for the development of the only Canadian AAES accredited fellowship program in Endocrine Surgery. Dr Pasieka has been Secretary-Treasurer of the American Association of Endocrine Surgeons (AAES) and in 2010 she became the first Canadian and second woman to become President. She has served on the Council of the International Association of Endocrine Surgeons (IAES), and in 2016 became the Secretary-Treasurer, a position she holds at the present time. Dr Pasieka was the Canadian James IV Traveling Surgical Fellow 2006 and recently was appointed to the James VI Board of Directors. In 2007, the Women’s Executive Network named her as one of Canada’s 100 Most Powerful Women. Dr Pasieka recently completed her 6 year term as a Governor of the American College of Surgeons. Her areas of interests (besides running, mountain biking, cycling and hiking & snowshoeing with her dog Kocher) evolve around neuroendocrine tumors, adrenal disease, thyroid cancer and the study of surgical outcomes in patients with hyperparathyroidism. To date she has 140 peer-review publications, has edited 3 Endocrine Surgical textbooks and written over 24 book chapters.



 

Rayson, Daniel 

Dr. Daniel Rayson is a medical oncologist at the Queen Elizabeth II Health Sciences Centre and Professor of Medicine and Pediatrics at Dalhousie University.  He completed his medical training at Dalhousie, with subsequent fellowship training in Internal Medicine and Hematology/Medical Oncology at the Mayo Clinic in Rochester, Minnesota.  His main areas of clinical care and research activities are in breast and neuroendocrine oncology.  He is past Chair of the Nova Scotia Provincial Breast Cancer Site Team (2000-2009), current Chair of the multidisciplinary Neuroendocrine Tumor Group (2012- ) and past chair of the Clinical Trial Grant Panel Review Committee of the National Cancer Institute of Canada (2006-2009). He has been the Director of the Atlantic Clinical Cancer Research Unit (ACCRU) since 2008, is on the editorial board of the Art of Oncology Section of the Journal of Clinical Oncology and has been section editor of the Cancer Narratives Section of Current Oncology since January 2013. In January 2015, he became Interim Chief of the Division of Medical Oncology at the QE II Health Sciences Center and Dalhousie University.



 

Turcotte, Éric

Many in medical community regard Dr Eric Turcotte as a leading authority and much-sought-after speaker on PET scan and PET tracer development.  His enthusiastic approach helps him to quickly connect with patients and scientists and make an impact.

Dr Turcotte graduated from University of Sherbrooke School of Medicine and completed his specialist training in Nuclear medicine.  He continued with post-doctoral fellowship in Nuclear medicine at University of Washington, Seattle (WA).

Dr Turcotte has over twenty years of experience in medical practice.  He practices medicine at Nuclear medicine department at Centre hospitalier Universitaire de Sherbrooke (CHUS) and is an Associate Professor at the University of Sherbrooke. He teaches nuclear medicine and PET imaging to students from Canada and around the world, as well as to many Canadian nuclear medicine specialists seeking special training in PET. As the head of Clinical research at Sherbrooke Molecular Imaging Centre (CIMS), Dr Turcotte has lead more than 30 clinical research studies. Dr Turcotte has been a contributing writer for books, has published dozens of articles, and speaks extensively on PET scan imagery and tracer development. 

Dr Turcotte is the leader of 8 clinical trial applications with Health Canada testing the diagnostic efficiency of newly developed PET tracers. His work also includes taking newly developed radiotracers from the pre-clinical development stage to a final human imaging or therapeutic modality phase. He also holds an establishment license from Health Canada to operate one of the most advanced PET radiotracer synthesis facilities in Canada.



 

Wong, Rebecca

Dr. Rebecca Wong is a radiation oncologist at Princess Margaret Cancer Center, Professor of the Department of Radiation Oncology, Past Vice-Chair for Education (2014-2020), Department of Radiation Oncology, University of Toronto.  Her clinical interests are the areas of gastrointestinal malignancies and palliative radiotherapy. She is a member of the CCO Radionuclide Therapy Operating Council & Executive Committee, and a member of the AJCC NET staging expert panel, and PI for the Ontario PRRT OZM 067 trial.

 


Powered by Wild Apricot Membership Software